CAR T-Cell Superior to Standard Therapy in Patients With NHL – Targeted Oncology
|
CAR T-Cell Superior to Standard Therapy in Patients With NHL
Targeted Oncology A standardized analyses of 2 clinical trials showed three-fourths of patients with refractory non-Hodgkin lymphoma (NHL) treated with the autologous anti-CD19 CAR T-cell therapy axicabtagene ciloleucel (axi-cel) achieved objective responses, compared … |
